CorePharma Recalls Pyridostigmine Bromide Tablets Due to Stability Failure
CorePharma is recalling 960 bottles of Pyridostigmine Bromide Tablets 60 mg because stability testing showed out-of-specification results.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically corresponds to a moderate severity where the probability of serious adverse health consequences is remote, and no specific injuries or illnesses are reported in the source text.
Plain-English summary
CorePharma, LLC is recalling 960 bottles of Pyridostigmine Bromide Tablets 60 mg, USP. The product is identified by NDC 64720-128-10, lot number 109497, and an expiration date of 12/15. The recall was initiated because the tablets failed stability specifications during testing, resulting in an out-of-specification test result.
The affected product was distributed nationwide. The recall is classified as Class II by the FDA, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Consumers and healthcare providers should stop using the affected product and contact their pharmacist or healthcare provider for guidance on replacement or return. The recall is limited to the specific lot and expiration date listed above.
The recalled product
- Product
- Pyridostigmine Bromide Tablets 60 mg, USP Rx Only 100 Tablets, Manufactured and Distributed by: CorePharma, LLC Middlesex, NJ 08846 NDC 64720-128-10 NDC 64720-128-10
- Manufacturer
- Core Pharma Llc
- Category
- Drug — Prescription Medication
- Affected units
- 960
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 109497
- Exp. 12/15
Distribution
Distributed nationwide across the United States.
Related recalls
Same hazard · stability failure
See all →- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
- ModerateSafecor Health Recalls Fluphenazine HCl Elixir Due to Stability Failures
FDA (Drugs) · 2026-09-23
Similar recalls
- ModerateCorepharma Recalls Pyridostigmine Bromide Tablets Due to Dissolution Failure
FDA (Drugs) · 2014-02-12
- LowLiothyronine Sodium Tablets Recalled for Failed Stability Testing
FDA (Drugs) · 2013-05-15
- SevereImpax Recalls Dextroamphetamine Sulfate Tablets Due to Failed Impurity Specifications
FDA (Drugs) · 2016-04-27
- ModerateMicro Labs Recalls Glimepiride Tablets Due to Failed Stability Testing
FDA (Drugs) · 2014-11-05
- ModeratePD-Rx Pharmaceuticals Recalls Famotidine 20 mg Tablets for Weight Issues
FDA (Drugs) · 2017-08-09
- ModerateAllergan Recalls One Lot of Viokace Tablets Due to Stability Testing Failures
FDA (Drugs) · 2018-01-17